Quick Answer
ARROWHEAD PHARMACEUTICALS, INC. reported Total Revenue of $829.45 million for fiscal year 2025.
ARROWHEAD PHARMACEUTICALS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $829.45M +23258.2% |
$3.55M -98.5% |
$240.74M -1.0% |
$243.23M +75.9% |
$138.29M +57.2% |
$87.99M -47.9% |
| Revenue (ASC 606) | $829.45M +23258.2% |
$3.55M -98.5% |
$240.74M -1.0% |
$243.23M +75.9% |
$138.29M +57.2% |
$87.99M -47.9% |
| Net Income | -$1.63M +99.7% |
-$599.49M -192.0% |
-$205.28M -16.6% |
-$176.06M -25.0% |
-$140.85M -66.6% |
-$84.55M -224.4% |
| Diluted EPS | -$0.01 +99.8% |
-$5.00 -160.4% |
-$1.92 -15.0% |
-$1.67 -22.8% |
-$1.36 -61.9% |
-$0.84 -221.7% |
| Total Assets | $1.39B +21.5% |
$1.14B +48.9% |
$765.55M +10.6% |
$691.94M -2.6% |
$710.15M +35.9% |
$522.50M +49.4% |
| Cash and Equivalents | — | — | — | — | $184.43M +28.5% |
$143.58M -35.3% |
| Stockholders Equity | $466.05M +151.3% |
$185.44M -31.7% |
$271.34M -31.9% |
$398.52M -2.5% |
$408.82M -11.5% |
$461.78M +88.8% |
| R&D Expense | $607.16M +20.0% |
$505.87M +43.2% |
$353.19M | — | — | — |
| Operating Income | $98.35M +116.4% |
-$601.08M -193.2% |
-$205.00M -14.8% |
-$178.51M -19.8% |
-$149.04M -60.0% |
-$93.16M -252.2% |
| Shares Outstanding | 135.70M +9.1% |
124.38M +15.9% |
107.31M +1.3% |
105.96M +1.6% |
104.33M +1.9% |
102.38M +7.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | December 31, 2025 | $264.03M | +10461.3% | +850.9% |
| Revenue (ASC 606) | December 31, 2025 | $264.03M | +10461.3% | +850.9% |
| Net Income | December 31, 2025 | $30.81M | +117.8% | +117.6% |
| Diluted EPS | December 31, 2025 | $0.22 | +115.8% | +117.5% |
| Total Assets | December 31, 2025 | $1.60B | +58.3% | +15.8% |
| Cash and Equivalents | June 30, 2022 | $139.44M | -57.2% | +61.4% |
| Stockholders Equity | December 31, 2025 | $568.42M | +980.9% | +22.0% |
| R&D Expense | December 31, 2025 | $177.20M | +29.3% | +29.3% |
| Operating Income | December 31, 2025 | $40.81M | +125.3% | +124.7% |
| Shares Outstanding | December 31, 2025 | 137.39M | +9.4% | +1.2% |
- ARROWHEAD PHARMACEUTICALS, INC. reported Total Revenue of $829.45 million for fiscal year 2025.
- ARROWHEAD PHARMACEUTICALS, INC. showed an increase of +23258.2% in Total Revenue compared to the prior fiscal year.
- ARROWHEAD PHARMACEUTICALS, INC. reported Revenue (ASC 606) of $829.45 million for fiscal year 2025.
- ARROWHEAD PHARMACEUTICALS, INC. showed an increase of +23258.2% in Revenue (ASC 606) compared to the prior fiscal year.
- ARROWHEAD PHARMACEUTICALS, INC. reported Net Income of -$1.63 million for fiscal year 2025.
- ARROWHEAD PHARMACEUTICALS, INC. showed an increase of +99.7% in Net Income compared to the prior fiscal year.
- ARROWHEAD PHARMACEUTICALS, INC. reported Diluted EPS of $0.01 per share (loss) for fiscal year 2025.
- ARROWHEAD PHARMACEUTICALS, INC. showed an increase of +99.8% in Diluted EPS compared to the prior fiscal year.
- ARROWHEAD PHARMACEUTICALS, INC. reported Total Assets of $1.39 billion for fiscal year 2025.
- ARROWHEAD PHARMACEUTICALS, INC. showed an increase of +21.5% in Total Assets compared to the prior fiscal year.
- ARROWHEAD PHARMACEUTICALS, INC. reported Cash and Equivalents of $184.43 million for fiscal year 2021.
- ARROWHEAD PHARMACEUTICALS, INC. showed an increase of +28.5% in Cash and Equivalents compared to the prior fiscal year.
- ARROWHEAD PHARMACEUTICALS, INC. reported Stockholders Equity of $466.05 million for fiscal year 2025.
- ARROWHEAD PHARMACEUTICALS, INC. showed an increase of +151.3% in Stockholders Equity compared to the prior fiscal year.
- ARROWHEAD PHARMACEUTICALS, INC. reported R&D Expense of $607.16 million for fiscal year 2025.
- ARROWHEAD PHARMACEUTICALS, INC. showed an increase of +20.0% in R&D Expense compared to the prior fiscal year.
- ARROWHEAD PHARMACEUTICALS, INC. reported Operating Income of $98.35 million for fiscal year 2025.
- ARROWHEAD PHARMACEUTICALS, INC. showed an increase of +116.4% in Operating Income compared to the prior fiscal year.
- ARROWHEAD PHARMACEUTICALS, INC. reported Shares Outstanding of 135.70 million shares for fiscal year 2025.
- ARROWHEAD PHARMACEUTICALS, INC. showed an increase of +9.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: